Compare · MURA vs NVO
MURA vs NVO
Side-by-side comparison of Mural Oncology plc (MURA) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MURA and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO carries a market cap of $183.82B.
- Over the past year, MURA is down 22.5% and NVO is down 36.8% - MURA leads by 14.3 points.
- NVO has hit the wire 6 times in the past 4 weeks while MURA has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 4 for MURA).
- Company
- Mural Oncology plc
- Novo Nordisk A/S
- Price
- $2.03-0.49%
- $41.17-0.02%
- Market cap
- -
- $183.82B
- 1M return
- -2.87%
- +14.28%
- 1Y return
- -22.52%
- -36.78%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 6
- Recent ratings
- 4
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest MURA
- Amendment: SEC Form SCHEDULE 13G/A filed by Mural Oncology plc
- SEC Form 15-12G filed by Mural Oncology plc
- SEC Form EFFECT filed by Mural Oncology plc
- SEC Form S-8 POS filed by Mural Oncology plc
- SEC Form S-8 POS filed by Mural Oncology plc
- SEC Form S-8 POS filed by Mural Oncology plc
- SEC Form POS AM filed by Mural Oncology plc
- SEC Form 4 filed by Director Hickey Benjamin
- Chief Executive Officer Loew Caroline returned 293,059 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Cuss Francis M
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S